Molecular Partners (Switzerland)
- Research works
- 90 ▲ 65% vs 2013–17
- Citations
- 1.9k 21.0 per fractional work
- Top-10% rate
- 15.9% record average 16.5%
- Open access
- 44% world 28%
Not ranked overall: Molecular Partners (Switzerland) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 6.3×. Every wedge is a field page.
- Immunology and Microbiology 6.3×
- Medicine 3.0×
- Energy 2.7×
- Biochemistry, Genetics and Molecular Biology 2.6×
- Business, Management and Accounting 1.9×
- Economics, Econometrics and Finance 1.3×
- Earth and Planetary Sciences 0.7×
- Neuroscience 0.6×
- Chemistry 0.4×
- Decision Sciences 0.4×
- Environmental Science 0.3×
- Materials Science 0.2×
- Engineering 0.2×
- Agricultural and Biological Sciences 0.2×
- Health Professions 0.1×
- Mathematics 0.1×
- Social Sciences 0.1×
- Physics and Astronomy 0.1×
- Psychology 0.1×
- Computer Science 0.1×
Who are the top researchers at Molecular Partners (Switzerland)?
Ranked on the composite score, Ulrike Fiedler, Christof Zitt and Keith M. Dawson lead among researchers whose main affiliation is Molecular Partners (Switzerland).
- 1 Ulrike Fiedler Switzerland · #796,545 worldwide 44 citations · 16 works
- 2 Christof Zitt Switzerland · #812,866 worldwide 59 citations · 17 works
- 3 Keith M. Dawson Switzerland · #1,319,354 worldwide 28 citations · 22 works
- 4 Christian Reichen Switzerland · #1,336,274 worldwide 10 citations · 15 works
Which keywords describe research at Molecular Partners (Switzerland)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Immunotherapy, Cancer Immunotherapy, Cancer Therapy, Tumor Microenvironment, Tumor Regression, CAR T Cells, Chimeric Antigen Receptor and Monoclonal Antibodies.
- Immunity
- Targeted Therapy
- Cardiovascular Disease
- Sustainability
- Immunosuppression
- Fibroblast Activation Protein
- Business Models
- Therapeutic Antibodies
- Inflammation
- Monoclonal Antibodies
- Climate Change
- CAR T Cells
- Tumor Microenvironment
- Immunotherapy
- Cancer Immunotherapy
- Cancer Therapy
- Tumor Regression
- Chimeric Antigen Receptor
- Epidemiology
- Fc Receptors
- PET Imaging
- Angiogenesis
- Cell Death
- Immune Checkpoint Blockade
- PD-1 and PD-L1
- BRCA Mutation
- PARP Inhibitors
- Dynamic Capabilities
- Knowledge Transfer
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 29 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 29 words, with their numbers
- Cancer Immunotherapy3▲ 62×3 topics
- Immunotherapy3▲ 13×11 topics
- Cancer Therapy3▲ 16×6 topics
- Tumor Microenvironment3▲ 19×6 topics
- Tumor Regression2▲ 66×2 topics
- CAR T Cells2▲ 94×1 topic
- Chimeric Antigen Receptor2▲ 94×1 topic
- Climate Change2▲ 1.99×7 topics
- Epidemiology2▲ 1.34×12 topics
- Monoclonal Antibodies2▲ 58×2 topics
- Fc Receptors2▲ 91×1 topic
- Inflammation2▲ 2.4×14 topics
- PET Imaging2▲ 29×2 topics
- Therapeutic Antibodies2▲ 71×1 topic
- Angiogenesis1▲ 13×3 topics
- Business Models1▲ 55×2 topics
- Cell Death1▲ 17×4 topics
- Fibroblast Activation Protein1▲ 89×1 topic
- Immune Checkpoint Blockade1▲ 37×1 topic
- Immunosuppression1▲ 43×1 topic
- PD-1 and PD-L11▲ 37×1 topic
- Sustainability1▲ 1.65×5 topics
- BRCA Mutation1▲ 164×1 topic
- Cardiovascular Disease1▲ 3.3×10 topics
- PARP Inhibitors1▲ 164×1 topic
- Targeted Therapy1▲ 16×4 topics
- Dynamic Capabilities1▲ 91×1 topic
- Immunity1▲ 8.3×5 topics
- Knowledge Transfer1▲ 69×1 topic
Which research topics does Molecular Partners (Switzerland) publish most on?
By volume in 2022–2025: CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research, Cancer Immunotherapy and Biomarkers and Peptidase Inhibition and Analysis.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CAR-T cell therapy research Oncology 2 works
- 2 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 4 Peptidase Inhibition and Analysis Oncology 1 works
- 5 PARP inhibition in cancer therapy Oncology 1 works
- 6 Innovation and Knowledge Management Strategy and Management 1 works
- 7 Phagocytosis and Immune Regulation Immunology 1 works
- 8 Medical Imaging and Pathology Studies Pulmonary and Respiratory Medicine 0 works
- 9 Advanced Biosensing Techniques and Applications Molecular Biology 0 works
- 10 Global Energy Security and Policy General Energy 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Molecular Partners (Switzerland)'s research output changed?
Output in 2018–2022 was 65% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Schlieren
- Spital Limmattal
- Cell Medica (Switzerland)
- Biognosys (Switzerland)
- Kuros Biosciences (Switzerland)
- Exalos (Switzerland)
- Neurotune (Switzerland)
- Foundation for People with Rare Diseases
- Arcadis (Switzerland)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.